| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, November 2007, p. 7906-7917, Vol. 27, No. 22
0270-7306/07/$08.00+0 doi:10.1128/MCB.01369-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
,
Laboratory of Signal Transduction,1 Laboratory of Neurobiology, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina 27709,2 Department of Pharmacology, University of Illinois College of Medicine, Chicago, Illinois 60612,3 Department of Biomedical Engineering, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599,4 Division of Medicine, Imperial College School of Medicine, London W12 0NN, United Kingdom5
Received 30 July 2007/ Accepted 4 September 2007
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Although ITSN is clearly linked with endocytosis, increasing evidence suggests that ITSN's role within the cell is not limited to this process (1, 10, 18, 19, 27-29, 32). The cloning of mammalian ITSN revealed a longer, spliced product containing a guanine nucleotide exchange factor domain specific for Cdc42 (10, 27). Through the EH domains, ITSN activates a Jun N-terminal protein kinase-dependent pathway that cooperates with growth factors and Ras to stimulate transcription and the oncogenic transformation of cells (1, 19, 32). In addition to interacting with endocytic proteins, the SH3 region of ITSN also interacts with several proteins that regulate cellular signaling pathways. For example, ITSN forms complexes with the guanine nucleotide exchange factor Sos to stimulate Ras activation specifically on endomembrane compartments (19). More recently, it has been shown that ITSN associates with the Cbl E3 ubiquitin ligase to regulate EGFR ubiquitylation, trafficking, signaling, and degradation (18).
While loss-of-function mutations in ITSN result in synaptic vesicle defects and lethality in Drosophila (14, 17), these mutant flies possess only mild endocytic defects, raising the possibility that the loss of ITSN may result in additional deficits, particularly in signaling pathways. To address this possibility, we have stably silenced ITSN expression in neuronal cells to determine the importance of this scaffold in neuron function. We demonstrate that ITSN directly interacts with a novel isoform of phosphoinositide 3'-kinase (PI3K) to regulate the survival of neuronal cells through the activation of a PI3K-AKT pathway. This effect is distinct from ITSN's involvement in endocytosis and indicates that ITSN function in the cell is pleiotrophic and not limited to regulation of the endocytic pathway.
| MATERIALS AND METHODS |
|---|
|
|
|---|
DNA constructs.
The yellow fluorescent protein (YFP)-tagged mouse ITSN (short isoform) and the constructs expressing HA-tagged ITSN and the EH, coiled-coil, and SH3 domains have been previously described (19). Glutathione S-transferase (GST) fusions with the individual SH3 domains were made by PCR of the following amino acids from mouse ITSN: SH3A, amino acids (aa) 738 to 801; SH3B, aa 909 to 963; SH3C, aa 998 to 1052; SH3D, aa 1070 to 1130; and SH3D, aa 1151 to 1209. Each fragment was designed with a BamHI site at the 5' end and an EcoRI site at the 3' end to clone into pGEX4T2. All clones were verified by DNA sequence analysis. Cyan fluorescent protein (CFP)-tagged PI3K-C2ß was subcloned from Glu-tagged PI3K-C2ß (2). Note that this PI3K-C2ß clone was N-terminally truncated due to an internal methionine. Thus, aa 1 corresponds to aa 26 in full-length PI3K-C2ß. The amino acid numbers of PI3K-C2ß refer to sequence CAA72168 (EMBL database). The insert was excised by EcoRI-XhoI digestion, and the ends were filled in to generate blunt ends. Plasmid pECFP was digested with EcoRI, and the ends were filled in and then ligated to the insert. The ends were sequenced to confirm that the insert was in the correct orientation and in frame. The N terminus of PI3K-C2ß (PI3K NT) fused to CFP (CFP-PI3K NT) was subcloned from the clone obtained from the yeast two-hybrid screen. A NotI fragment containing amino acids G18 to V475 was excised, and the ends were filled and then ligated to pECFP that had been previously digested with SmaI and dephosphorylated. The sequence of inserts was confirmed by DNA sequence analysis. The GST fusion proteins with PI3K NT (aa 27 to 356 as noted above) and the C2 domains of PI3K-C2
were as described previously (2). HA-Akt, Myr-Akt-HA, and HA-Akt-K179A were a gift from Al Baldwin, University of North Carolina, Chapel Hill, NC.
Construction of silencing vectors. Pairs of oligonucleotides were annealed and then ligated into pSuperRetro.puro, referred to as pSR (Oligoengine), and digested with BglII and HindIII. The pLVTH lentiviral vector (35) was derived by subcloning the EcoRI-ClaI fragment of pSR-M1635 into pLVTH digested with EcoRI and ClaI. The oligonucleotides used to generate the short hairpin RNA (shRNA) constructs used in this study are as follows: R111-5, 5'GATCCCCAGCATGACCAGCAGTTCCATTCAAGAGATGGAACTGCTGGT CATGCTTTTTT; R111-3, 5'AGCTAAAAAAGCATGACCAGCAGTTCCATCTCTTGAATGGAACTGCTGGTCATGCTGGG; M207-5, 5'GATCCCCCGATGGAACGATGGATCAATTCAAGAGATTGATCCATCCTTCCA TCGTTTTT; M207-3, 5'AGCTAAAAACGATGGAAGGATGGATCAATCTCTTGAATTGATCCATCGTTCCATCGGGG; M268-5, 5'GATCCCCCAAGGATATCAGCTCCCCTTTCAAGAGAAGGGGAGCTGATATCCTTG TTTTT; M268-3, 5'AGCTAAAAACAAGGATATCAGCTCCCCTTCTCTTGAAAGGGGAGCTGATATCCTTGGGG; M599-5, 5'GATCCCCAGGCACAATCATTCGATGTTTCAAGAGAACATCGAATGATTGTGCCTTT TTT; M599-3, 5'AGCTAAAAAAGGCACAATCATTCGATGTTCTCTTGAAACATCGAATGATTGTGCCTGGG; M739-5, 5'GATCCCCACTATTCTCATGCAATCAATTCAAGAGATTGATTGCATGAGAATAGTTTTTT; M739-3, 5'AGCTAAAAAACTATTCTCATGCAATCAATCTCTTGAATTGATTGCATGAGAATAGTGGG; M1635-5, 5'GTCCCCGATACTCAGTGACCAGTTATTCAAGAGATAACTGGTCACTGAGTATCTTTTT; M1635-3, 5'AGCTAAAAAGATACTCAGTGACCAGTTATCTCTTGAATAACTGGTCACTG AGTATCGGG; miRNA-5, 5'GATCCCCGGATATCAGCTCCCCTCCATTCAAGAGATGGAGGGGAGCTGATATCCTTTTTGGAAA; and miRNA-3, 5'AGCTTTTCCAAAAAGGATATCAGCTCCCCTCCATCTCTTGAATGGAGGGGAGCTGATATCCGGG.
Description of PI3K Pro-rich mutants. Mutation of Pro-rich domain 1 (PRD1) (aa 156 to 161; PPPLPP to AAALAA) and PRD2 (aa 169 to173; PPLPP to AALAA) in full-length pECFP-PI3K-C2ß was carried out using a two-step site-directed PCR mutagenesis approach. Two pairs of oligonucleotides were used for generating the first-step PCR products—a 0.6-kb PRD1 fragment using primers pECFP5'621 (5' CTGCCCGACAACCACTACCTG 3') and PI3KPR1-3'PA (5' AGCGGTATCCCAGATAGAAGCTCGGGCAGCCAGAGCAGCTGCGGATAGTTTC 3') and a 0.5-kb PRD2 fragment using primers PI3KPR2-5'PA (5' CGAGCTTCTATCTGGGATACCGCTGCCCTAGCTGCCAGAAAGGGGTC 3') and PI3KPR2-3' (5' AGAGCCAGATGCAAGGATATCCAGCA 3'). These two PCR fragments were mixed, reamplified using pECFP5'621 and PI3KPR2-3' as primer pairs, subcloned into pCR4-topo-TA, and subjected to DNA sequence analysis. This construct was digested with XhoI and EcoRV to release the PI3K fragment, which was subcloned into a pECFP Xho-EcoRV fragment produced by digestion of the pECFP-PI3K-C2ß construct above with XhoI and EcoRV that releases the wild-type N-terminal fragment, the XhoI-EcoRV fragment (aa 27 to 345), and a 4-kb EcoRV PI3K fragment (aa 346 to 1634). The resulting construct encodes the Pro-to-Ala (PA) mutant CFP-PI3K NT PA. We then digested this construct with EcoRV and subcloned the 4-kb EcoRV PI3K fragment to generate the full-length PI3K PA mutant. The wild-type PI3K NT construct was obtained by subcloning the N-terminal XhoI-EcoRV fragment of PI3K (aa 27 to 345) into the pECFP Xho-EcoRV fragment above. For both the wild type and the PA mutant of PI3K NT, the cloning strategy results in an additional 25 amino acids on the C terminus (KLIDTVDLEILQSTVPRARDPPDLI), derived from the vector.
Differentiation of N1E-115 cells. N1E-115 cells or stable subclones were plated at a density of 20,000 cells per well in six-well plates or 200,000 cells per 10-cm dish in complete medium (DMEM with 10% fetal bovine serum). On the following day, the medium was replaced with DMEM containing 0.1% bovine serum albumin (BSA) and no serum (differentiation medium). Cells were examined for differentiation as evidenced by changes in cell morphology and the production of neurites for 4 days following serum withdrawal. The images were recorded by using a Nikon digital camera attached to a Nikon inverted microscope. Each plate of cells in differentiation medium was paired with a plate of cells in complete medium for comparison. The experiments were done in duplicate and repeated at least three times. To quantify the cell death during differentiation, we used a CellTiter-Glo luminescent cell viability assay kit (Promega).
Yeast two-hybrid assay.
Analysis was performed through a contract with Myriad Genetics essentially as described previously (31), except that the various individual domains of mouse or human ITSN were used as bait. To confirm the yeast two-hybrid assay results with ITSN and PI3K, the Saccharomyces cerevisiae yeast strain AH109 (MATa trp1-901 leu2-3,112 ura3-52 his3-200 gal4
gal80
LYS2::GAL1UAS-GAL1TATA-HIS3 GAL2UAS-GAL2TATA-ADE2 URA3::MEL1UAS-MEL1TATA-lacZ) was transformed with ITSN:pGBT.Q/bait (aa 730 to 816 of ITSN) and PI3K-C2ß:pGAD.PN2/prey (aa 18 to 475 of PI3K-C2ß). Additionally, each plasmid, with corresponding empty vectors or both empty vectors, was also tested for growth on medium lacking histidine.
Phosphoinositide kinase assays.
Confluent cell cultures were incubated in the absence or presence of EGF at 37°C for the times indicated and then lysed at 4°C in cell lysis buffer (10 mM Tris-HCl [pH 7.6], 5 mM EDTA, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 100 µM Na3VO4, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride). The lysates were clarified by centrifugation (13,000 x g, 20 min), and the supernatants were transferred to a fresh tube and used for immunoprecipitation as indicated below. Kinase assays were performed in a total volume of 30 µl containing 20 mM HEPES, pH 7.4, 100 mM NaCl, 0.1 mM EGTA, 0.1 mM EDTA, and 200 µg/ml phosphatidylinositol (Sigma). After sonicated lipid was preincubated with the sample for 10 min, the reaction was initiated by adding divalent cation (6 mM) and 100 µM ATP (0.2 µCi [
-32P]ATP). The assay mixtures were incubated at 30°C for 20 min and then terminated with acidified chloroform/methanol (1:1, vol/vol). The extracted phosphoinositide products were fractionated by thin-layer chromatography and visualized by autoradiography. All assays were linear with respect to time and enzyme addition.
AKT activation assays. COS cells were transiently cotransfected with the expression constructs indicated in Fig. 4A along with an HA epitope-tagged AKT expression construct. Following an overnight incubation in serum-free medium, the cells were stimulated with EGF, the lysates harvested, and Western blot assays performed to assess the expression of HA-AKT. The lysates were normalized so that equal amounts of HA-AKT were immunoprecipitated with an HA monoclonal antibody. The precipitates were washed three times with ice-cold phospholipase C (PLC)-LB containing inhibitors and then resuspended in 25 µl of 4x NuPAGE sample buffer supplemented with 5% ß-mercaptoethanol. After being heated to 70°C for 10 min, equivalent amounts of samples were fractionated on duplicate 4 to 12% NuPAGE gels (Invitrogen), transferred to Immobilon-P membranes, and probed with antibodies to the HA epitope to determine the total levels of AKT or antibodies to activated AKT (pSer473; New England Biolabs). The activation levels were determined by densitometric analysis of Western blots to determine the pAKT and total AKT levels. The activation (n-fold) was determined by dividing the level of pAKT by that of total AKT and normalizing to unstimulated, vector control sample (YFP or LVTH alone). The experiments were performed in triplicate.
|
. Briefly, a 50-ml culture was grown at 37°C until the cell density reached 1 as measured by absorbance at 600 nm. The cultures were then induced with isopropyl-ß-D-thiogalactopyranoside (IPTG) (0.1 mM), grown for an additional 3 h, and spun down. The cell pellet was lysed in 5 ml of B-PER solution (Pierce) supplemented with protease inhibitors and incubated at 4°C for 20 min on a nutator. The debris was pelleted, and the supernatant was placed in a new tube. A total of 200 µl of washed glutathione-agarose beads was added to the supernatant, and the mixture was incubated at 4°C for 2 h on the nutator, after which the beads were pelleted, washed three times with incubation buffer (25 mM HEPES, pH 7.2, 0.5% Triton X-100, 125 mM potassium acetate, 2.5 mM magnesium acetate, 5 mM EGTA, supplemented with 1 mM dithiothreitol and protease inhibitors), and resuspended in a final volume of 250 µl (including beads). A 10-µl amount of the slurry was run on a gel to estimate the concentration of the purified proteins.
Cell lysates were prepared from HA-tagged ITSN or mock-transfected HEK 293T cells. Forty-eight hours after transfection, the cells were washed with warm phosphate-buffered saline (PBS) and lysed in PLC lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl2, and 100 mM NaF) supplemented with protease inhibitors. After 30 min at 4°C on a nutator, the soluble lysates were obtained by centrifugation at 14,000 rpm for 10 min and used for the GST pull-down assay. One milligram of protein was added to 0.5 µg of the purified PI3K-C2
C2 or PI3K NT fusion protein or GST as a control and mixed on the nutator at 4°C for 2 h. At the end of the incubation, 20 µl of washed glutathione-agarose beads were added to the mixture so that the beads would be more visible. The beads were spun down and washed three times with the incubation buffer described above and then resuspended in 30 µl of LDS sample buffer (Invitrogen). The samples were fractionated on a gel, transferred to an Immobilon-P membrane, and probed with antibodies against HA. The blots were developed with SuperSignal chemiluminescence reagent (Pierce).
Confocal microscopy.
Confocal images were acquired using a Carl Zeiss LSM 510 mounted on an Axiovert 100 M microscope. Images were obtained using a 514 nm argon laser for YFP and 458 nm for CFP with a Plan-Apochromat 63x/1.4 oil immersion objective lens. A 531- to 595-nm-wavelength bandpass filter was used for YFP emission, and a 470- to 500-nm-wavelength bandpass filter was used for CFP, with a pinhole of 0.7 Airy units, which provides a z resolution of
0.6 um.
BiFC assays. Bimolecular fluorescence complementation (BiFC) expression constructs consisting of the NH2 terminus or COOH terminus of Venus (VN and VC, respectively) were kindly provided by Chang-Deng Hu (25). ITSN or PI3K was cloned into these vectors such that the Venus fragments were fused to the NH2 terminus of the respective protein. COS cells were transiently transfected late in the day and then imaged the following morning so that the various proteins were not vastly overexpressed. CFP was cotransfected along with the BiFC constructs, but at a fivefold-lower amount, to mark transfected cells.
Endocytosis assays. For analysis of fluorescent transferrin internalization, cells were serum starved for 60 min in the presence of 2% BSA and then incubated with Alexa 488-conjugated transferrin (50 µg/ml; Molecular Probes) for 15 min at 37°C. The cells were then washed in cold PBS, acid washed (0.2 N acetic acid-0.5 M NaCl) one time for 8 min, rinsed in PBS, and then fixed in 4% paraformaldehyde. Cells were analyzed by using a Zeiss LSM 510 META confocal microscope (excitation, 488 nm; filters, 505 to 530 nm), and z-stacks were collected for 20 to 25 cells per cell line for two different sets of cells. The images were imported into the three-dimensional-imaging software Volocity 3.70, and the total fluorescence was quantified for the entire z-stack. For analysis of the internalization of biotinylated transferrin, cells were treated with biotinylated transferrin (50 µg/ml; Sigma) as described above and then lysed in PLC-LB buffer. The biotinylated transferrin levels in the lysates were quantified by Western blotting with a streptavidin antibody. Changes in fluid-phase endocytosis were quantified by measurement of horseradish peroxidase (HRP) uptake according to previously published methods (16). Briefly, cells were serum starved, incubated with HRP (5 mg/ml; Sigma) for 1 h at 37°C, washed five times with cold PBS-1% BSA, and lysed in PBS-0.1% Triton X-100. The HRP internalization was then quantified by using 3,3-diaminobenzidine tablets (Sigma) and reading the absorbance at 490 nm.
TUNEL staining. Apoptotic cells were identified by terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) staining using an Apo-Direct kit from Calbiochemical. Cells were counterstained with Hoechst 33258 (Molecular Probes), and the percent TUNEL-positive cells was determined by counting the number of TUNEL-Hoechst double-positive cells and dividing by the total number of Hoechst-positive cells. More than 250 total Hoechst-positive cells were scored for each time point.
| RESULTS |
|---|
|
|
|---|
|
|
and
isoforms, and class III PI3Ks. Using GST pull-down experiments, we found that the N terminus of PI3K-C2ß containing the two Pro-rich sequences was sufficient to bind ITSN, whereas neither GST nor GST-PI3K-C2
C2 domain interacted with ITSN (Fig. 4D).
|
Immunocytochemical staining of endogenous ITSN and PI3K-C2ß revealed that a portion of these two proteins colocalized in cells (Fig. 5A). We were unable to coprecipitate endogenous ITSN and PI3K-C2ß, possibly due to the fact that the antibodies target epitopes in the regions of interaction between ITSN and PI3K-C2ß. Therefore, we analyzed the interaction of epitope-tagged versions of the two proteins. This approach also allowed us to determine whether both isoforms of ITSN interacted with PI3K-C2ß. Both the HA-tagged short and long ITSN isoforms associated with PI3K-C2ß (Fig. 5B). The data from the yeast two-hybrid assay and cell-free experiments demonstrated that the SH3 domains of ITSN, specifically, SH3A, bound PI3K-C2ß. In support of these results, we observed that only the full-length ITSN and the isolated SH3 domains associated with endogenous PI3K-C2ß from cell lysates, whereas the remaining regions were not sufficient for stable interaction (Fig. 5C). PI3K-C2ß was not present in the HA immunoprecipitates from vector-, EH-, EH-coil-, or coil-transfected cell lysates, indicating that this interaction was specific to the SH3 domains of ITSN. To determine the importance of the Pro-rich motifs in PI3K-C2ß for interaction with ITSN, we mutated the Pro to Ala in both motifs. These mutations abolished the interaction of ITSN with both full-length PI3K-C2ß and PI3K NT (Fig. 5D). However, deletion of SH3A from ITSN did not inhibit the interaction of ITSN with PI3K-C2ß, suggesting that these two proteins interact in a multivalent fashion. Similar results were reported for the interaction of ITSN with Cbl (18). These data demonstrate that ITSN requires the Pro-rich motifs of PI3K-C2ß for stable association.
|
|
|
The ITSN-PI3K-AKT pathway regulates neuron cell survival. To determine whether ITSN's role in cell survival in neuronal cells (Fig. 1 and 2) was related to its ability to stimulate PI3K activity in epithelial cells (Fig. 7), we treated N1E-115 cells with LY294002. As with the silencing of ITSN, PI3K inhibition decreased cell survival during differentiation (Fig. 8A). Similarly, the stable expression of dominant-negative AKT (AKT DN) decreased the survival of differentiating N1E-115 cells (Fig. 8B and C). Thus, inhibition of the PI3K-AKT pathway phenocopied loss of ITSN. Conversely, the overexpression of either PI3K-C2ß (Fig. 8D) or AKT (Fig. 8E and F) in ITSN-silenced N1E-115 cells rescued the survival of these cells during differentiation; however, neither the expression of CFP alone (Fig. 8D), PI3K NT (data not shown), nor AKT DN (Fig. 8E and F) rescued ITSN-silenced cells. Although ITSN regulates the endocytic pathway, these results appear to be independent of this activity, as neither transferrin internalization nor uptake of HRP were inhibited in ITSN-silenced cells compared to rescued ITSN-silenced cells, e.g., M1635 plus CFP-PI3K, M1635 plus AKT, or control cells (Fig. 3 and 9). These results demonstrate that ITSN regulates neuron survival through the activation of a PI3K-C2ß-AKT signaling pathway.
|
|
| DISCUSSION |
|---|
|
|
|---|
This current study reveals a critical role for ITSN in regulating the survival of differentiating neurons through the regulation of a PI3K-C2ß-AKT pathway. We demonstrate that ITSN and PI3K-C2ß are associated and that growth factor enhances both the interaction of these two proteins and the activation of PI3K-C2ß by ITSN. While PI3K activation and PtdIns(3,4,5)P3 levels have been thought to occur mainly at the plasma membrane, recent studies indicate that RTKs stimulate phosphatidylinositol-3,4,5-trisphosphate [PtdIns(3,4,5)P3] production on endocytic vesicles (23) and that these PtdIns(3,4,5)P3-positive vesicles are trafficked to the plasma membrane through a kinesin-dependent process (8). In neurons, this transport is necessary for determining polarity and specifying axon development (8). Our data suggest that ITSN-PI3K-C2ß may contribute to PtdIns(3,4,5)P3 generation on intracellular vesicles. Although this interaction of ITSN was specific to PI3K-C2ß, both PI3K-C2
and PI3K-C2ß interact with clathrin, resulting in enhanced lipid kinase activity and PtdIns(3,4,5)P3 production (6, 33). This interaction appears to be important for the dynamic cycling of clathrin from vesicles at the plasma membrane, as well as in the trans-Golgi network (6). The activation of AKT in ITSN-overexpressing cells is consistent with the model that ITSN stimulates PI3K-C2ß, resulting in increased PtdIns(3,4,5)P3 synthesis and activation of AKT.
PI3K-C2ß is a member of the larger family of PI3Ks that consist of three distinct classes, each of which phosphorylates the 3' hydroxyl position of the inositol ring of phosphatidylinositol-derived lipids (30). Class II PI3Ks have been implicated in trafficking events due to their association with the trans-Golgi network and clathrin-coated vesicles (6) and their ability to regulate both clathrin-dependent endocytosis and protein transport (5, 6). In addition, class II PI3Ks are downstream targets of activated receptors, resulting in the activation of AKT (3, 33, 34). Given the cooperativity between ITSN and RTKs (1, 11, 20), the association of ITSN with PI3K-C2ß may represent an important step in the regulation of PI3K-C2ß activity by growth factor receptors.
These studies demonstrate an important role for ITSN in cell survival through the regulation of phosphoinositide metabolism. The association of ITSN with synaptojanin I, an endocytic protein containing two phosphoinositide phosphatase domains (7), suggests that this multidomain scaffold may regulate both the production and the turnover of multiple phosphoinositides in vivo. Deletion of synaptojanin I results in altered phosphoinositide levels in the brain, with an increase in PtdIns(4,5)P2 levels (4). Interestingly, an increase in clathrin-coated vesicles and a decrease in the recycling of these vesicles was observed upon the deletion of synaptojanin I, consistent with its proposed role in vesicle trafficking. Synaptojanin I mutant animals exhibited enhanced synaptic depression, as well as neurologic defects, and died soon after birth (4). Thus, the association of ITSN with both PI3K-C2ß and synaptojanin I suggests that this scaffolding molecule may play a central role in the dynamic regulation of phosphoinositides in vivo.
Our previous results indicated that transient silencing of ITSN resulted in decreased internalization of the EGFR, whereas the stably silenced N1E-115 cells did not exhibit defects in internalization. The lack of a gross endocytic defect in the stably silenced cells is not surprising, since the Dap160 loss-of-function mutants exhibit very mild endocytic defects which only become apparent during high-frequency stimulation of the synapse (14, 17). Thus, these mild defects may not be detectable under the conditions used in these studies. Furthermore, it is possible that the remaining ITSN in the cells is sufficient for maintaining endocytosis but not for the regulation of PI3K activity. Regardless, it is clear that the survival defect in the ITSN-silenced cells is rescued by the expression of either PI3K-C2ß or AKT, both of which are activated downstream of ITSN.
Although class I PI3Ks regulate cell survival through the activation of AKT, our data demonstrate that PI3K-C2ß plays a critical role in this process as well. Furthermore, our results reveal an important role for ITSN in regulating this PI3K-C2ß-AKT survival pathway. Indeed, loss-of-function alleles of Drosophila ITSN resulted in larval lethality (14, 17), consistent with this possibility. In addition, a recent study by Predescu and colleagues (22) demonstrated that transient silencing of ITSN in human microvascular endothelial cells activated a mitochondrial apoptotic pathway, leading to death of the ITSN-silenced cells. However, the mechanism by which ITSN protects cells from apoptosis was not determined. Our silencing experiments demonstrate that the specific depletion of ITSN from neuronal cells decreased the survival both of differentiating N1E-115 cells and primary cortical neurons, which could be rescued by the overexpression of either PI3K-C2ß or AKT. Interestingly, constitutive endocytosis was unaffected in the ITSN-silenced cells, rescued cells, or cells expressing AKT DN (Fig. 8). Thus, ITSN regulates cell survival, independent of its role in endocytosis, through the activation of a novel PI3K-C2ß-AKT pathway.
| ACKNOWLEDGMENTS |
|---|
We thank Albert Baldwin for providing the ATK constructs, Chang-Deng Hu for the BiFC constructs, and Dieder Trono for the pLVTH lentiviral system. We thank Jeff Reese and Yawer Husain for assistance with the confocal imaging and quantification of transferrin fluorescence and Michael Stewart for quantification of N1E-115 cell survival. We also thank Athar Chishti, David Armstrong, and Fernando Ribeiro-Neto for helpful comments on the manuscript and members of the O'Bryan lab for many helpful discussions.
This work was funded in part by the intramural research program of the NIH (J.P.O.), support from a Concern Foundation grant (J.P.O.), and start-up funds from the University of Illinois at Chicago (J.P.O.).
| FOOTNOTES |
|---|
Published ahead of print on 17 September 2007. ![]()
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Arcaro, A., S. Volinia, M. J. Zvelebil, R. Stein, S. J. Watton, M. J. Layton, I. Gout, K. Ahmadi, J. Downward, and M. D. Waterfield. 1998. Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J. Biol. Chem. 273:33082-33090.
3. Arcaro, A., M. J. Zvelebil, C. Wallasch, A. Ullrich, M. D. Waterfield, and J. Domin. 2000. Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol. Cell. Biol. 20:3817-3830.
4. Cremona, O., G. Di Paolo, M. R. Wenk, A. Luthi, W. T. Kim, K. Takei, L. Daniell, Y. Nemoto, S. B. Shears, R. A. Flavell, D. A. McCormick, and P. De Camilli. 1999. Essential role of phosphoinositide metabolism in synaptic vesicle recycling. Cell 99:179-188.[CrossRef][Medline]
5. Domin, J., I. Gaidarov, M. E. Smith, J. H. Keen, and M. D. Waterfield. 2000. The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the trans-Golgi network and present in clathrin-coated vesicles. J. Biol. Chem. 275:11943-11950.
6. Gaidarov, I., M. E. Smith, J. Domin, and J. H. Keen. 2001. The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol. Cell 7:443-449.[CrossRef][Medline]
7. Guo, S., L. E. Stolz, S. M. Lemrow, and J. D. York. 1999. SAC1-like domains of yeast SAC1, INP52, and INP53 and of human synaptojanin encode polyphosphoinositide phosphatases. J. Biol. Chem. 274:12990-12995.
8. Horiguchi, K., T. Hanada, Y. Fukui, and A. H. Chishti. 2006. Transport of PIP3 by GAKIN, a kinesin-3 family protein, regulates neuronal cell polarity. J. Cell Biol. 174:425-436.
9. Hu, C. D., Y. Chinenov, and T. K. Kerppola. 2002. Visualization of interactions among bZIP and Rel family proteins in living cells using bimolecular fluorescence complementation. Mol. Cell 9:789-798.[CrossRef][Medline]
10. Hussain, N. K., S. Jenna, M. Glogauer, C. C. Quinn, S. Wasiak, M. Guipponi, S. E. Antonarakis, B. K. Kay, T. P. Stossel, N. Lamarche-Vane, and P. S. McPherson. 2001. Endocytic protein intersectin-l regulates actin assembly via Cdc42 and N-WASP. Nat. Cell Biol. 3:927-932.[CrossRef][Medline]
11. Irie, F., and Y. Yamaguchi. 2002. EphB receptors regulate dendritic spine development via intersectin, Cdc42 and N-WASP. Nat. Neurosci. 5:1117-1118.[CrossRef][Medline]
12. Jenna, S., N. K. Hussain, E. I. Danek, I. Triki, S. Wasiak, P. S. McPherson, and N. Lamarche-Vane. 2002. The activity of the GTPase-activating protein CdGAP is regulated by the endocytic protein intersectin. J. Biol. Chem. 277:6366-6373.
13. Kimhi, Y., C. Palfrey, I. Spector, Y. Barak, and U. Z. Littauer. 1976. Maturation of neuroblastoma cells in the presence of dimethylsulfoxide. Proc. Natl. Acad. Sci. USA 73:462-466.
14. Koh, T. W., P. Verstreken, and H. J. Bellen. 2004. Dap160/intersectin acts as a stabilizing scaffold required for synaptic development and vesicle endocytosis. Neuron 43:193-205.[CrossRef][Medline]
15. Letunic, I., R. R. Copley, S. Schmidt, F. D. Ciccarelli, T. Doerks, J. Schultz, C. P. Ponting, and P. Bork. 2004. SMART 4.0: towards genomic data integration. Nucleic Acids Res. 32:D142-D144.
16. Li, G., and P. D. Stahl. 1993. Structure-function relationship of the small GTPase rab5. J. Biol. Chem. 268:24475-24480.
17. Marie, B., S. T. Sweeney, K. E. Poskanzer, J. Roos, R. B. Kelly, and G. W. Davis. 2004. Dap160/intersectin scaffolds the periactive zone to achieve high-fidelity endocytosis and normal synaptic growth. Neuron 43:207-219.[CrossRef][Medline]
18. Martin, N. P., R. P. Mohney, S. Dunn, M. Das, E. Scappini, and J. P. O'Bryan. 2006. Intersectin regulates epidermal growth factor receptor endocytosis, ubiquitylation, and signaling. Mol. Pharmacol. 70:1643-1653.
19. Mohney, R. P., M. Das, T. G. Bivona, R. Hanes, A. G. Adams, M. R. Philips, and J. P. O'Bryan. 2003. Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK. J. Biol. Chem. 278:47038-47045.
20. Nishimura, T., T. Yamaguchi, A. Tokunaga, A. Hara, T. Hamaguchi, K. Kato, A. Iwamatsu, H. Okano, and K. Kaibuchi. 2006. Role of numb in dendritic spine development with a Cdc42 GEF intersectin and EphB2. Mol. Biol. Cell 17:1273-1285.
21. O'Bryan, J. P., R. P. Mohney, and C. E. Oldham. 2001. Mitogenesis and endocytosis: what's at the INTERSECTIoN? Oncogene 20:6300-6308.[CrossRef][Medline]
22. Predescu, S. A., D. N. Predescu, I. Knezevic, I. K. Klein, and A. B. Malik. 2007. Intersectin-1s regulates the mitochondrial apoptotic pathway in endothelial cells. J. Biol. Chem. 282:17166-17178.
23. Sato, M., Y. Ueda, T. Takagi, and Y. Umezawa. 2003. Production of PtdInsP3 at endomembranes is triggered by receptor endocytosis. Nat. Cell Biol. 5:1016-1022.[CrossRef][Medline]
24. Sengar, A. S., W. Wang, J. Bishay, S. Cohen, and S. E. Egan. 1999. The EH and SH3 domain Ese proteins regulate endocytosis by linking to dynamin and Eps15. EMBO J. 18:1159-1171.[CrossRef][Medline]
25. Shyu, Y. J., H. Liu, X. Deng, and C. D. Hu. 2006. Identification of new fluorescent protein fragments for bimolecular fluorescence complementation analysis under physiological conditions. BioTechniques 40:61-66.[Medline]
26. Simpson, F., N. K. Hussain, B. Qualmann, R. B. Kelly, B. K. Kay, P. S. McPherson, and S. L. Schmid. 1999. SH3-domain-containing proteins function at distinct steps in clathrin-coated vesicle formation. Nat. Cell Biol. 1:119-124.[CrossRef][Medline]
27. Snyder, J. T., D. K. Worthylake, K. L. Rossman, L. Betts, W. M. Pruitt, D. P. Siderovski, C. J. Der, and J. Sondek. 2002. Structural basis for the selective activation of Rho GTPases by Dbl exchange factors. Nat. Struct. Biol. 9:468-475.[CrossRef][Medline]
28. Tong, X. K., N. K. Hussain, A. G. Adams, J. P. O'Bryan, and P. S. McPherson. 2000. Intersectin can regulate the Ras/MAP kinase pathway independent of its role in endocytosis. J. Biol. Chem. 275:29894-29899.
29. Tong, X. K., N. K. Hussain, E. de Heuvel, A. Kurakin, E. Abi-Jaoude, C. C. Quinn, M. F. Olson, R. Marais, D. Baranes, B. K. Kay, and P. S. McPherson. 2000. The endocytic protein intersectin is a major binding partner for the Ras exchange factor mSos1 in rat brain. EMBO J. 19:1263-1271.[CrossRef][Medline]
30. Vanhaesebroeck, B., and M. D. Waterfield. 1999. Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res. 253:239-254.[CrossRef][Medline]
31. von Schwedler, U. K., M. Stuchell, B. Muller, D. M. Ward, H. Y. Chung, E. Morita, H. E. Wang, T. Davis, G. P. He, D. M. Cimbora, A. Scott, H. G. Krausslich, J. Kaplan, S. G. Morham, and W. I. Sundquist. 2003. The protein network of HIV budding. Cell 114:701-713.[CrossRef][Medline]
32. Wang, J. B., W. J. Wu, and R. A. Cerione. 2005. Cdc42 and Ras cooperate to mediate cellular transformation by intersectin-L. J. Biol. Chem. 280:22883-22891.
33. Wheeler, M., and J. Domin. 2006. The N-terminus of phosphoinositide 3-kinase-C2beta regulates lipid kinase activity and binding to clathrin. J. Cell. Physiol. 206:586-593.[CrossRef][Medline]
34. Wheeler, M., and J. Domin. 2001. Recruitment of the class II phosphoinositide 3-kinase C2ß to the epidermal growth factor receptor: role of Grb2. Mol. Cell. Biol. 21:6660-6667.
35. Wiznerowicz, M., and D. Trono. 2003. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol. 77:8957-8961.
36. Yamabhai, M., N. G. Hoffman, N. L. Hardison, P. S. McPherson, L. Castagnoli, G. Cesareni, and B. K. Kay. 1998. Intersectin, a novel adaptor protein with two Eps15 homology and five Src homology 3 domains. J. Biol. Chem. 273:31401-31407.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||